Request Demo
Last update 01 Apr 2025
Wyckoff Heights Medical Center, Inc.
Last update 01 Apr 2025
Overview
Related
NCT01315808
Rate of Change of HbA1c (dx/dt) May Predict Progression to Type 2 DM: Comparing the Concept of dx/dt With QD Diabetes Prediction Model. D.E.R.M.S Initiative (Doctor Enabled Risk Management System)
100 Clinical Results associated with Wyckoff Heights Medical Center, Inc.
Login to view more data
Login to view more data
01 Apr 2025SEMINARS IN ARTHRITIS AND RHEUMATISM
Prioritising domains of glucocorticoid therapy to measure in trials: Results from a modified delphi exercise from the OMERACT glucocorticoid impact working group
Article
Author: Robson, Joanna C ; Cheah, Jonathan Tl ; Tieu, Joanna ; Lyne, Suellen ; Hill, Catherine L ; Yip, Kevin ; Mackie, Sarah L ; Ghosh, Nilasha ; Goodman, Susan M ; Christensen, Robin ; Black, Rachel J ; Richards, Pamela
INTRODUCTION:
There is no consensus amongst patients and healthcare professionals about how to measure important adverse effects of glucocorticoids (GCs) that includes the patient's perspective. The OMERACT GC Impact working group sought to identify the domains of greatest importance to both patients and healthcare professionals for use in a proposed core outcome set.
METHODS:
Patients and healthcare professionals participated in a Delphi consensus exercise to rate the importance of previously identified candidate domains. Those deemed critical to include by at least 70% in both groups, after three rounds of a Delphi exercise were identified as meeting consensus. All participants were asked which additional domains should be measured in all trials in a final survey; those domains selected by more than 70% of all participants were added, resulting in a final list of potential core domains.
RESULTS:
In total, 363 people (295 patients and 68 healthcare professionals) participated in the Delphi process. The final list of potential core domains included: bone fragility, diabetes, eye problems and/or changes in vision, high blood pressure, infection, osteonecrosis, mood disturbance, fatigue, sleep disturbance, weight.
CONCLUSION:
The 10 domains identified through this exercise informed the proposed core domain set of GC effects to be considered for use in future clinical trials involving GCs. This core domain set was endorsed at the OMERACT 2020 virtual workshop.
01 Feb 2025VALUE IN HEALTH
Prescription Medication Use and Expenditure for Atrial Fibrillation in the United States
Article
Author: Patel, Neel ; Roma, Nicholas ; Munir, Muhammad Bilal ; Seetharam, Karthik ; Balla, Sudarshan ; Padala, Vikram ; Lacoste, Jordan ; Gonuguntla, Karthik ; Thyagaturu, Harshith
OBJECTIVES:
To study the national trends of anticoagulants, antiarrhythmic drugs (AADs), and expenditures in the civilian noninstitutionalized atrial fibrillation (AF) population.
METHODS:
The Medical Expenditure Panel Survey was queried from January 2016 to December 2021 to identify adults (age ≥18 years) with a diagnosis of AF utilizing the International Classification of Diseases, Tenth Revision, Clinical Modification code I48. Prevalence of anticoagulants (AAD) and its expenditure and AF expenditure across clinical settings in the United States were estimated. The predictors of anticoagulant use were identified utilizing multivariate logistic regression analysis.
RESULTS:
A total of 17.3 million AF adults were identified, of which 46.5% were female, 89.6% were White, and ∼70% were middle/high income with prevalent comorbidities of hypertension (75.3%) and coronary heart disease (30%). The mean CHA2DS2 VASc score was 3.2, and 40% had a score of ≥4. In the United States, an average of $26 103 (2021 inflation adjusted) was spent per year per adult with AF for health-related expenditures. The prevalence of direct oral anticoagulants (DOACs) and class I AAD use has increased; in contrast, vitamin K antagonists use has declined. DOAC-related per person annual expenses increased from $849 in 2016 to $1929 in 2021. In those with a CHA2DS2 VASc score of ≥2, female sex and the presence of coronary heart disease were associated with a lower likelihood of anticoagulant use.
CONCLUSIONS:
AF is a costly condition in which prescription medication use, such as DOACs and class III AADs, are significant contributors.
29 Jan 2025Cureus Journal of Medical Science
Unmasking Euglycemic Diabetic Ketoacidosis: The Interplay of Pregnancy, Sepsis, and Glucagon-Like Peptide 1 Analog
Article
Author: Huang, Alice ; Gossen, Isabel M ; Lazarescu, Roxana ; Pancotto, Nicole ; Reyes, July M ; Lu, Jenny ; Sekhon, Gagandeep S
Euglycemic diabetic ketoacidosis (EDKA) is a life-threatening, yet under-recognized, complication of type 1 and type 2 diabetes. EDKA is characterized by metabolic acidosis and ketonemia in the absence of significant hyperglycemia. The absence of ketoacidosis-related complications may delay diagnosis, leading to severe consequences. Common precipitating factors include medication use (e.g., sodium-glucose cotransporter 2 inhibitors), acute illnesses (e.g., sepsis), trauma, and pregnancy. We report the case of a 35-year-old pregnant female with a history of type 2 diabetes, hypertension, and hyperlipidemia who presented with a two-day history of chills, shoulder pain, and reduced range of motion. The patient was compliant with dulaglutide, but not insulin. She had a history of chronic left shoulder pain managed with intraarticular corticosteroid injections, and imaging showed no evidence of fracture. The patient was admitted for septic arthritis of the left shoulder. During her hospital stay, she developed an elevated anion gap metabolic acidosis with a small elevation in her blood glucose. She tested positive for ketonuria and glucosuria. Upon admission, she deteriorated and was transferred to the intensive care unit for the management of EDKA. An insulin drip was initiated, leading to the resolution of her anion gap and resolving the ketoacidosis. This case underscores the importance of recognizing EDKA, particularly in the context of rising glucagon-like peptide 1 receptor agonist use for diabetes and weight management. EDKA remains a rare but serious condition, and timely identification and management are critical in preventing morbidity. This report also emphasizes the need for heightened clinical suspicion of EDKA in pregnant or septic patients with diabetes, even when blood glucose levels do not suggest diabetic ketoacidosis.
100 Deals associated with Wyckoff Heights Medical Center, Inc.
Login to view more data
100 Translational Medicine associated with Wyckoff Heights Medical Center, Inc.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 02 May 2025
No data posted
Login to keep update
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free